ClinicalTrials.gg
Not yet recruitingNCT06874166Updated Mar 13, 2025

Social Cognition in Dystrophinopathies and Neurodevelopmental Disorders

An observational study in Duchenne / Becker Muscular Dystrophy, Osteogenesis Imperfecta (OI) and Social Cognition, sponsored by IRCCS Eugenio Medea. Not yet recruiting. Open to male participants aged 4 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-03-13.

Sponsored by IRCCS Eugenio Medea · Observational

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
45
Ages
4 Years and older
Sex
Male
01

Study summary

The primary aim of this observational study is to investigate specific aspects of social cognition in dystrophinopathies. Body awareness, interpersonal distance and emotional processing will be measured in a sample of patients affected by Becker (BMD) and Duchenne (DMD) muscular dystrophy, compared with a sample of patients affected by osteogenesis imperfecta (OI), and both compared with a control sample with typical development.

The secondary aim is to study cortical activity at rest, by means of electroencephalography (EEG), to explore frequencies and time course of EEG responses. Moreover, the relationship between EEG activity and neuropsychological, dispositional and subjective measures will be explored through correlational analyses.

Read the detailed description

Study procedure includes: 1. Eligibility assessment according to inclusion and exclusion criteria. 2. Administration of questionnaires and scales for the characterization of cognitive and psychological features related with BMD/DMD and OI : Wechsler Intelligence Scale for Children 4th Edition (WISC-IV), Raven's Progressive Matrices; NEPSY-II; The Child Behavior Checklist (CBCL); PedsQL; Toronto Alexithymia Scale (TAS-20); Emotion Regulation Questionnaire (ERQ); Emotion Regulation Questionnaire for Children and Adolescents (ERQ-CA); Multidimensional Assessment of Interoceptive Awareness (MAIA); Body Shape Questionnaire (BSQ-14); and the Autism Spectrum Quotient (AQ, adult or child version) 3. Administration of experimental tasks. The Comfort-Distance Task (CDT) to measure the interpersonal comfort distance, the task will be implemented in immersive virtual reality by means of head-mounted displays (OCULUS ©2024 Meta). Interoceptive accuracy will be measured through a modified version of the heartbeat counting task. An emotional priming task will be administered in order to measure emotion processing, participants will be asked to detect trial by trial the target emotion which could be preceded by a congruent or incongruent visual priming.

All the tasks will be performed in a counterbalanced order, for an overall duration of about 40 minutes.

  1. Recording of resting state EEG will be collected.
02

Conditions studied

  • Duchenne / Becker Muscular Dystrophy
  • Osteogenesis Imperfecta (OI)
  • Social Cognition

Keywords

  • Social Cognition
  • Duchenne / Becker muscular dystrophy
  • Osteogenesis Imperfecta (OI)
  • EEG
  • Interpersonal distance
  • Interoception
03

In context

Muscular Dystrophy, Duchenne

481 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 108 are open to participants now.

This study's planned enrollment of 45 is below the median of 60 across 132 observational studies indexed under Muscular Dystrophy, Duchenne.

Browse Muscular Dystrophy, Duchenne studies →

Lead sponsor

IRCCS Eugenio Medea is the lead sponsor of 108 studies on the registry; 51 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
4 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

For the statistical power analysis the size of the effect reported in Candini et al., 2017 (η2p = 0.28) has been considered, about the effect of diagnostic features on the peripersonal space, and the effect reported by Garcia et al., 2023 (η2p = 0.20) about the differences between DMD/BMD patients and neurotypicals in social cognition. The calculation, performed separately for the two different effects, returns a sample size between 17 and 23 minimum patients per group.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients diagnosed with Duchenne and Becker muscular dystrophy (genetic and histological diagnosis and clinical diagnosis) (ambulant and non-ambulant).
  • Patients diagnosed with osteogenesis imperfecta.
  • Control group: participants without any neurological or psychiatric disorder

Exclusion criteria

Exclusion Criteria:

  • presence of comorbid diagnoses,
  • sensory deficit
  • specific condition that could prevent the application of the tests and tasks under study, such as: a) the need for PEG; b) the need for tracheostomy; c) the need for assisted ventilation.
  • cognitive level lower than 60.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
45 participants (estimated)
Patient registry
No

Groups and cohorts

  • BMD/DMD group

    Patients diagnosed with Duchenne and Becker muscular dystrophy (genetic and histological diagnosis and clinical diagnosis) (ambulant and non-ambulant), over the age of four.

    Other: Electroencephalography (EEG) · Other: Social Cognition Tasks

  • OI group

    Patients diagnosed with osteogenesis imperfecta, over the age of four.

    Other: Electroencephalography (EEG) · Other: Social Cognition Tasks

  • Control group

    Participants without any neurological or psychiatric disorder, over the age of four.

    Other: Electroencephalography (EEG) · Other: Social Cognition Tasks

Interventions

  • OtherElectroencephalography (EEG)

    Recording of resting state EEG will be collected

  • OtherSocial Cognition Tasks

    Comfort-Distance Task: it will be used to measure the interpersonal comfort distance, the task will be implemented in immersive virtual reality environment Interoception will be measured through an auditory match task based on participants heart-beat A measure emotion processing will be collected through the emotion priming visual task, participants will be asked to detect trial by trial the target emotion which could be preceded by a congruent or incongruent visual priming

06

What researchers measure

Primary outcomes

  1. Interoception

    interoceptive index

    Time frame: Day 1

  2. Interpersonal distance

    Interpersonal comfort distance, measured in meters (m) within the virtual environment

    Time frame: Day 1

  3. Emotional processing

    Visual priming task performance

    Time frame: Day 1

  4. EEG power

    EEG alpha power

    Time frame: once

  5. EEG power

    EEG beta power

    Time frame: Day 1

  6. EEG power

    EEG theta power

    Time frame: Day 1

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2025; primary completion for Sep 2027, 24 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2025
First posted
Mar 13, 2025
StartEst.
Sep 2025
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Mar 13, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06874166
Responsible party
Sponsor
First posted
Mar 13, 2025
Start date
Sep 2025 (estimated)
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 13, 2025

Study contacts

Valentina Nicolardi, PhD
Contact
valentina.nicolardi@lanostrafamiglia.it
0039 + 3200598331

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion